• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    6/4/24 4:31:10 PM ET
    $ASXC
    $AZTR
    $CCM
    $CLDI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASXC alert in real time by email

    Gainers

    • Concord Medical Services (NYSE:CCM) shares moved upwards by 131.0% to $4.85 during Tuesday's after-market session. The company's market cap stands at $210.6 million.
    • Calidi Biotherapeutics (AMEX:CLDI) stock increased by 4.26% to $0.21. The market value of their outstanding shares is at $10.8 million.
    • Anitra (AMEX:AZTR) shares moved upwards by 2.69% to $0.18. The market value of their outstanding shares is at $5.0 million.
    • MAIA Biotechnology (AMEX:MAIA) stock rose 0.79% to $3.79. The company's market cap stands at $82.7 million.
    • Emergent BioSolutions (NYSE:EBS) shares moved upwards by 0.53% to $5.59. The market value of their outstanding shares is at $292.9 million.
    • Asensus Surgical (AMEX:ASXC) shares increased by 0.38% to $0.24. The market value of their outstanding shares is at $64.4 million.

    Losers

    • BiomX (AMEX:PHGE) stock fell 4.7% to $0.4 during Tuesday's after-market session. The market value of their outstanding shares is at $28.0 million.
    • SunLink Health Systems (AMEX:SSY) shares declined by 3.8% to $0.68. The company's market cap stands at $4.7 million.
    • Scorpius Holdings (AMEX:SCPX) shares fell 3.55% to $0.12. The market value of their outstanding shares is at $11.8 million.
    • MultiPlan (NYSE:MPLN) shares decreased by 1.19% to $0.47. The market value of their outstanding shares is at $300.1 million.
    • IGC Pharma (AMEX:IGC) shares fell 0.97% to $0.47. The company's market cap stands at $35.4 million.
    • Nanoviricides (AMEX:NNVC) shares decreased by 0.78% to $2.4. The company's market cap stands at $28.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ASXC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASXC
    $AZTR
    $CCM
    $CLDI

    CompanyDatePrice TargetRatingAnalyst
    NanoViricides Inc.
    $NNVC
    12/16/2025Buy
    Alliance Global Partners
    Emergent BioSolutions Inc.
    $EBS
    12/30/2024$15.00Buy
    H.C. Wainwright
    Emergent BioSolutions Inc.
    $EBS
    8/22/2024$16.00Buy
    Rodman & Renshaw
    MultiPlan Corporation
    $MPLN
    6/26/2024$2.00Neutral
    Piper Sandler
    Emergent BioSolutions Inc.
    $EBS
    3/7/2024$5.00Hold → Buy
    The Benchmark Company
    Calidi Biotherapeutics Inc.
    $CLDI
    11/22/2023$11.00Buy
    H.C. Wainwright
    Emergent BioSolutions Inc.
    $EBS
    11/20/2023Underweight
    JP Morgan
    Asensus Surgical Inc.
    $ASXC
    11/16/2023Overweight → Neutral
    Cantor Fitzgerald
    More analyst ratings

    $ASXC
    $AZTR
    $CCM
    $CLDI
    SEC Filings

    View All

    SEC Form DEFA14A filed by MAIA Biotechnology Inc.

    DEFA14A - MAIA Biotechnology, Inc. (0001878313) (Filer)

    4/7/26 9:04:09 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by MAIA Biotechnology Inc.

    DEF 14A - MAIA Biotechnology, Inc. (0001878313) (Filer)

    4/7/26 9:02:15 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Calidi Biotherapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

    4/2/26 5:00:27 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASXC
    $AZTR
    $CCM
    $CLDI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on NanoViricides

    Alliance Global Partners initiated coverage of NanoViricides with a rating of Buy

    12/16/25 8:59:58 AM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Emergent BioSolutions with a new price target

    H.C. Wainwright initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $15.00

    12/30/24 7:24:57 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Emergent BioSolutions with a new price target

    Rodman & Renshaw initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $16.00

    8/22/24 7:22:39 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASXC
    $AZTR
    $CCM
    $CLDI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness

    GAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced a series of initiatives designed to help increase access to NARCAN® Nasal Spray and encourage the public to be ready to respond to an opioid overdose. These include the launch of the new NARCAN® Nasal Spray Carrying Case, the expanded availability of NARCAN® Nasal Spray multipacks and a college campus engagement featuring Pro Football Hall of Famer, Emmitt Smith and Release Recovery Founder/CEO, Zac Clark at Southern Methodist University (SMU). The new NARCAN® Nasal Spray Carrying Case is designed to be easy to carry, compact, discreet and durable, helping to ensure it's on hand whe

    4/7/26 8:05:00 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform's Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy

    SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American Society of Gene and Cell Therapy (ASGCT) annual meeting in Boston, Massachusetts on May 14, 2026. The Company will present data on its RedTail platform. RedTail is Calidi's systemically delivered virotherapy platform designed to selectively target tumors, remodel the tumor microenvironment (TME), and enable high-level expression of therapeutic genetic payloads directly at the tumor site while limiting peripheral exposure. Data presented at the ASGCT meeting

    4/7/26 8:00:00 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026

    SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American Association of Cancer Research (AACR) annual meeting in San Diego, California from April 17-22, 2026. The Company will demonstrate new data on its approach of simultaneously activating T-cells while inducing the expression of T-cell engagers specifically in situ in the tumor microenvironment (TME). RedTail is Calidi's systemically delivered virotherapy platform designed to selectively target tumors, remodel the TME, and enable high-level expression of thera

    4/1/26 8:00:00 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASXC
    $AZTR
    $CCM
    $CLDI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Smith Stan bought $9,959 worth of shares (2,700 units at $3.69) and received a gift of 20,000 shares (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    1/12/26 8:44:30 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Smith Stan bought $69,999 worth of shares (57,189 units at $1.22) (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    12/23/25 8:18:50 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Chaouki Steven M bought $49,999 worth of shares (40,849 units at $1.22), increasing direct ownership by 37% to 151,873 units (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    12/23/25 8:16:48 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASXC
    $AZTR
    $CCM
    $CLDI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Prins Richard K

    4 - IGC Pharma, Inc. (0001326205) (Issuer)

    4/6/26 4:02:50 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Mukunda Ram

    4 - IGC Pharma, Inc. (0001326205) (Issuer)

    4/6/26 4:02:29 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Moran James P

    4 - IGC Pharma, Inc. (0001326205) (Issuer)

    4/6/26 4:02:01 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASXC
    $AZTR
    $CCM
    $CLDI
    Leadership Updates

    Live Leadership Updates

    View All

    BiomX Adds Former Mossad Deputy to Advisory Board

    NETANYA, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE), today announced the appointment of Dr. Ehud (Udi) Levi to its newly formed Advisory Board.  Dr. Levi will support the Company in evaluating and pursuing strategic alternatives and business opportunities, with an emphasis on security and defense, aerial response systems, and counter-UAS (C-UAS) technologies. This will include identifying and assessing potential partnerships, transactions, and new business directions aligned with the Company's expansion into security and defense applications. Dr. Levi brings more than three decades of experience in Israeli intelligence and national security. He served in Unit 8200

    3/30/26 9:28:34 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth

    Seasoned financial leaders join BiomX to support strategic execution and advancement of the companyDOVER, Del. and NESS ZIONA, Israel, March 9, 2026 /PRNewswire/ -- BiomX Inc. (NYSE:PHGE), a clinical-stage company developing natural and engineered phage therapies designed to target and destroy harmful bacteria in chronic diseases, today announced the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer. Oster brings extensive experience in corporate strategy, mergers and acquisitions, and operational leadership across capital-intensive industries including energy, infrastructure, and industrial sectors. Throughout his career, he has led complex

    3/9/26 9:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors

    GAITHERSBURG, Md., March 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of John D. Fowler, Jr. to its board of directors effective March 1, 2026. Mr. Fowler brings more than three decades of leadership experience across the healthcare and financial services sectors. He will serve on the Audit and Finance Committee. "We're pleased to welcome John to the board of directors at this important point in the company's ongoing turnaround and transformation," said Dr. Zsolt Harsanyi, Ph.D., chairman of the board. "John's deep experience in healthcare and financial markets will provide valuable insight as the company continues to execute against i

    3/3/26 8:00:00 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASXC
    $AZTR
    $CCM
    $CLDI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Calidi Biotherapeutics Inc.

    SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

    11/14/24 2:05:25 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Azitra Inc

    SC 13G/A - Azitra, Inc. (0001701478) (Subject)

    11/14/24 12:56:51 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Azitra Inc

    SC 13G/A - Azitra, Inc. (0001701478) (Subject)

    11/14/24 12:18:21 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASXC
    $AZTR
    $CCM
    $CLDI
    Financials

    Live finance-specific insights

    View All

    Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results

    Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 millionFourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37%Full Year 2025 Net Income of $52.6 million versus a Net Loss of $190.6 million in the prior yearFull Year 2025 Net Income per diluted share of $0.93 versus a Net Loss per diluted share of $3.60 in the prior yearFull Year 2025 Adjusted Net Income of $86.8 million versus an Adjusted Net Loss of $12.1 million in the prior yearFull Year 2025 Adjusted Net Income per diluted share of $1.53 versus an Adjusted Net Loss per diluted share of $0.23 in the prior yearFull Year 2025 Gross Margin % of 45% and Adjusted Gross Margin % of

    2/26/26 4:05:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year of 2025. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of

    2/12/26 9:02:20 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BiomX Announces $3.0 Million Private Placement

    NESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered into definitive agreements in connection with a private investment in public equity ("Private Placement") financing for expected gross proceeds of approximately $3.0 million, before deducting placement agent fees and other offering expenses. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. About the Private PlacementIn the Private Placement, the Company agreed to issue and sell shares of its Se

    12/29/25 8:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care